

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

House JOINT RESOLUTION NO. 18

INTRODUCED BY *Rep. Brungton* *Morgan*

A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA URGING CONGRESS TO ENACT LEGISLATION TO REVISE THE PROCESS BY WHICH NEW DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES ARE APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION.

WHEREAS, improving patient access to quality health care is a paramount national goal; and

WHEREAS, the key to improved health care, especially for persons with serious unmet medical needs, is the rapid approval of safe and effective new drugs, biological products, and medical devices; and

WHEREAS, minimizing the delay between discovery and eventual approval of a new drug, biological product, or medical device derived from research conducted by innovative pharmaceutical and biotechnology companies could improve the lives of millions of Americans; and

WHEREAS, current limitations on the dissemination of information about pharmaceutical products reduce the availability of information to physicians, other health care professionals, and patients and unfairly restrict the right of free speech guaranteed by the first amendment to the United States Constitution; and

WHEREAS, the current rules and practices governing the review of new drugs, biological products, and medical devices by the United States Food and Drug Administration can delay approvals and are usually unnecessarily expensive.

NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA:

That the Legislature respectfully urge the Congress of the United States to address this important issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness.

BE IT FURTHER RESOLVED, that copies of this resolution be sent by the Secretary of State to the President of the United States, the Speaker of the United States House of Representatives, the President of the United States Senate, and to each member of the United States Senate and the House of

1 Representatives.

2

-END-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

House JOINT RESOLUTION NO. 18

INTRODUCED BY *Debra Brunson*

A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA URGING CONGRESS TO ENACT LEGISLATION TO REVISE THE PROCESS BY WHICH NEW DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES ARE APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION.

WHEREAS, improving patient access to quality health care is a paramount national goal; and

WHEREAS, the key to improved health care, especially for persons with serious unmet medical needs, is the rapid approval of safe and effective new drugs, biological products, and medical devices; and

WHEREAS, minimizing the delay between discovery and eventual approval of a new drug, biological product, or medical device derived from research conducted by innovative pharmaceutical and biotechnology companies could improve the lives of millions of Americans; and

WHEREAS, current limitations on the dissemination of information about pharmaceutical products reduce the availability of information to physicians, other health care professionals, and patients and unfairly restrict the right of free speech guaranteed by the first amendment to the United States Constitution; and

WHEREAS, the current rules and practices governing the review of new drugs, biological products, and medical devices by the United States Food and Drug Administration can delay approvals and are usually unnecessarily expensive.

NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA:

That the Legislature respectfully urge the Congress of the United States to address this important issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness.

BE IT FURTHER RESOLVED, that copies of this resolution be sent by the Secretary of State to the President of the United States, the Speaker of the United States House of Representatives, the President of the United States Senate, and to each member of the United States Senate and the House of

1 Representatives.

2

-END-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

INTRODUCED BY

House JOINT RESOLUTION NO. 18
DeBruijn Moran

A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA URGING CONGRESS TO ENACT LEGISLATION TO REVISE THE PROCESS BY WHICH NEW DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES ARE APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION.

WHEREAS, improving patient access to quality health care is a paramount national goal; and

WHEREAS, the key to improved health care, especially for persons with serious unmet medical needs, is the rapid approval of safe and effective new drugs, biological products, and medical devices; and

WHEREAS, minimizing the delay between discovery and eventual approval of a new drug, biological product, or medical device derived from research conducted by innovative pharmaceutical and biotechnology companies could improve the lives of millions of Americans; and

WHEREAS, current limitations on the dissemination of information about pharmaceutical products reduce the availability of information to physicians, other health care professionals, and patients and unfairly restrict the right of free speech guaranteed by the first amendment to the United States Constitution; and

WHEREAS, the current rules and practices governing the review of new drugs, biological products, and medical devices by the United States Food and Drug Administration can delay approvals and are usually unnecessarily expensive.

NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA:

That the Legislature respectfully urge the Congress of the United States to address this important issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness.

BE IT FURTHER RESOLVED, that copies of this resolution be sent by the Secretary of State to the President of the United States, the Speaker of the United States House of Representatives, the President of the United States Senate, and to each member of the United States Senate and the House of

1 Representatives.

2

-END-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

House JOINT RESOLUTION NO. 18

INTRODUCED BY *Debra Kaye*

A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA URGING CONGRESS TO ENACT LEGISLATION TO REVISE THE PROCESS BY WHICH NEW DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES ARE APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION.

WHEREAS, improving patient access to quality health care is a paramount national goal; and

WHEREAS, the key to improved health care, especially for persons with serious unmet medical needs, is the rapid approval of safe and effective new drugs, biological products, and medical devices; and

WHEREAS, minimizing the delay between discovery and eventual approval of a new drug, biological product, or medical device derived from research conducted by innovative pharmaceutical and biotechnology companies could improve the lives of millions of Americans; and

WHEREAS, current limitations on the dissemination of information about pharmaceutical products reduce the availability of information to physicians, other health care professionals, and patients and unfairly restrict the right of free speech guaranteed by the first amendment to the United States Constitution; and

WHEREAS, the current rules and practices governing the review of new drugs, biological products, and medical devices by the United States Food and Drug Administration can delay approvals and are usually unnecessarily expensive.

NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF MONTANA:

That the Legislature respectfully urge the Congress of the United States to address this important issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new drugs, biological products, and medical devices, without compromising patient safety or product effectiveness.

BE IT FURTHER RESOLVED, that copies of this resolution be sent by the Secretary of State to the President of the United States, the Speaker of the United States House of Representatives, the President of the United States Senate, and to each member of the United States Senate and the House of

1 Representatives.

2

-END-

1 HOUSE JOINT RESOLUTION NO. 18
2 INTRODUCED BY DEBRUYCKER, MESAROS

3
4 A JOINT RESOLUTION OF THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE STATE OF
5 MONTANA URGING CONGRESS TO ENACT LEGISLATION TO REVISE THE PROCESS BY WHICH NEW,
6 DRUGS, BIOLOGICAL PRODUCTS, AND MEDICAL DEVICES ARE APPROVED BY THE UNITED STATES
7 FOOD AND DRUG ADMINISTRATION.

8
9 WHEREAS, improving patient access to quality health care is a paramount national goal; and

10 WHEREAS, the key to improved health care, especially for persons with serious unmet medical
11 needs, is the rapid approval of safe and effective new drugs, biological products, and medical devices; and

12 WHEREAS, minimizing the delay between discovery and eventual approval of a new drug, biological
13 product, or medical device derived from research conducted by innovative pharmaceutical and
14 biotechnology companies could improve the lives of millions of Americans; and

15 WHEREAS, current limitations on the dissemination of information about pharmaceutical products
16 reduce the availability of information to physicians, other health care professionals, and patients and unfairly
17 restrict the right of free speech guaranteed by the first amendment to the United States Constitution; and

18 WHEREAS, the current rules and practices governing the review of new drugs, biological products,
19 and medical devices by the United States Food and Drug Administration can delay approvals and are usually
20 unnecessarily expensive.

21
22 NOW, THEREFORE, BE IT RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES OF THE
23 STATE OF MONTANA:

24 That the Legislature respectfully urge the Congress of the United States to address this important
25 issue by enacting comprehensive legislation to facilitate the rapid review and approval of innovative new
26 drugs, biological products, and medical devices, without compromising patient safety or product
27 effectiveness.

28 BE IT FURTHER RESOLVED, that copies of this resolution be sent by the Secretary of State to the
29 President of the United States, the Speaker of the United States House of Representatives, the President
30 of the United States Senate, and to each member of the United States Senate and the House of

1 Representatives.

2

-END-